Scholar IQ
Try ScholarIQ free
Upload Records Snowball Search Search OpenAlex
About the database
On this page:OverviewPublicationsKey papers
ScholarIQanswers from OpenAlex & ORCID

Sven R. Olson

ResearcherPublications, citations & collaboration network

Sven R. Olson is a researcher indexed in ScholarIQ from OpenAlex & ORCID. ScholarIQ records 74 works, 1,905 citations, an h-index of 23 and an i10-index of 35.

74
Works
1,905
Citations
23
h-index
35
i10-index

How has Sven R. Olson's publication output changed over time?

ScholarIQpublication output · 2014–2021

Output grew0% over the shown period — from 1 works in 2014 to 1 in 2021.

1
1
5
3
1
20142018201920202021

What are the most-cited papers on Sven R. Olson?

ScholarIQmost cited works
Thrombosis and Bleeding in Extracorporeal Membrane Oxygenation (ECMO) Without Anticoagulation: A Systematic Review
Sven R. Olson, Catherine R. Murphree, David Zonies, Andrew Meyer, Owen J. T. McCarty, Thomas G. DeLoughery, Joseph J. Shatzel
ASAIO Journal. 2020277 CitationsOPEN ACCESS
The many roles of tranexamic acid: An overview of the clinical indications for TXA in medical and surgical patients
Johnny Cai, Jessica Ribkoff, Sven R. Olson, Vikram Raghunathan, Hanny Al‐Samkari, Thomas G. DeLoughery, Joseph J. Shatzel
European Journal Of Haematology. 2019253 CitationsOPEN ACCESS
The role of iron repletion in adult iron deficiency anemia and other diseases
Benjamin Elstrott, Lubna Khan, Sven R. Olson, Vikram Raghunathan, Thomas G. DeLoughery, Joseph J. Shatzel
European Journal Of Haematology. 2019163 CitationsOPEN ACCESS
The contact activation inhibitor AB023 in heparin-free hemodialysis: results of a randomized phase 2 clinical trial
Christina U. Lorentz, Erik I. Tucker, Norah G. Verbout, Joseph J. Shatzel, Sven R. Olson, Brandon D. Markway, Michael Wallisch, Martina Ralle, Monica T. Hinds, Owen J. T. McCarty, David Gailani, Jeffrey I. Weitz, András Gruber
Blood. 2021117 CitationsOPEN ACCESS
Contact Activation Inhibitor and Factor XI Antibody, AB023, Produces Safe, Dose-Dependent Anticoagulation in a Phase 1 First-In-Human Trial
Christina U. Lorentz, Norah G. Verbout, Michael Wallisch, Matthew Hagen, Joseph J. Shatzel, Sven R. Olson, Cristina Puy, Monica T. Hinds, Owen J. T. McCarty, David Gailani, András Gruber, Erik I. Tucker
S3485792. 2019101 CitationsOPEN ACCESS

Related on ScholarIQ

Oregon Health & Science University
Institution
Thrombosis and Bleeding in Extracorporeal Membrane Oxygenation (ECMO) Without Anticoagulation: A Systematic Review
Paper
The many roles of tranexamic acid: An overview of the clinical indications for TXA in medical and surgical patients
Paper
The role of iron repletion in adult iron deficiency anemia and other diseases
Paper
The contact activation inhibitor AB023 in heparin-free hemodialysis: results of a randomized phase 2 clinical trial
Paper
Contact Activation Inhibitor and Factor XI Antibody, AB023, Produces Safe, Dose-Dependent Anticoagulation in a Phase 1 First-In-Human Trial
Paper
470M+ articles · free account